PT - JOURNAL ARTICLE AU - Rose, Shawn AU - Toloza, Sergio AU - Bautista-Molano, Wilson AU - Helliwell, Philip S. TI - Comprehensive Treatment of Dactylitis in Psoriatic Arthritis AID - 10.3899/jrheum.140879 DP - 2014 Nov 01 TA - The Journal of Rheumatology PG - 2295--2300 VI - 41 IP - 11 4099 - http://www.jrheum.org/content/41/11/2295.short 4100 - http://www.jrheum.org/content/41/11/2295.full SO - J Rheumatol2014 Nov 01; 41 AB - Dactylitis, a hallmark clinical feature of psoriatic arthritis (PsA) and other spondyloarthropathies, may also be a severity marker for PsA and psoriasis. Traditionally, clinicians have used nonsteroidal antiinflammatory drugs and local corticosteroid injections to treat dactylitis, although conventional disease-modifying antirheumatic drugs are also used. We performed a systematic literature review to determine the most efficacious current treatment options for dactylitis in PsA. Effect sizes were greatest for the biologic agents ustekinumab, certolizumab, and infliximab, suggesting that therapy with one of these agents should be initiated in patients with dactylitis. However, the limited data highlight the need for randomized, placebo-controlled trials, with dactylitis as a primary outcome, to determine a valid, reliable, and responsive clinical outcome measure for PsA patients with dactylitis.